Drug major sees better China sales

Drug maker Merck Sharp & Dohme (MSD) expects the pace of sales in China to accelerate due to government initiatives to improve public healthcare, said Michel Vounatsos, president of MSD China.

The size of MSD's China business will grow by 20 percent in the near future, the president said in an interview with China Daily.

"The signs are positive for pharmaceutical companies in China," said Vounatsos. "The problem is how to participate in the remarkable reforms."